Dystonia Drugs Market Expected to Reach $1,378.67 million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Dystonia Drugs Market," The dystonia drugs market size was valued at $806.67 million in 2021, and is estimated to reach $1,378.67 million by 2031, growing at a CAGR of 5.5% from 2022 to 2031.

A neurological condition characterized by excessive involuntary muscle contraction is termed dystonia. Muscle contractions lead to abnormal muscle movements and body postures, which makes it difficult for the person to control one's movements. Dystonia can be often painful and repetitive in nature. Although dystonia has no specific cause, it can occur as a result of chemical imbalance in the part of the brain known as the basal ganglia. In addition, conditions such as brain injury during or around the time of birth, certain infections, brain trauma, or various vascular abnormalities such as stroke, arteriovenous and others can also lead to dystonia.

Furthermore, treatment for dystonia includes non-drug therapies, oral medications, botulinum toxins, surgery, deep brain stimulation and other complementary therapies. Many medications have been shown to improve the condition of dystonia. Oral medications are commonly prescribed by the healthcare providers for treating dystonia owing to its cost effectiveness and easy availability as compared to other treatment options such as painful surgeries. This increases the demand for anticholinergic drugs, benzodiazepines, baclofen, dopaminergic agents and others for the treatment of dystonia. In addition, increase in prevalence of other neurological conditions an also increase the incidence of dystonia, which further increases the demand for dystonia drugs. This propels the dystonia drugs market growth.

In addition, an increase in R&D activities in the field of medicine is expected to drive the market during the forecast period. There has been a huge advancement in the healthcare sector, owing to an increase in research activities carried out by scientists and researchers in the field of medicine. Furthermore, there is an increase in awareness among the population of developed and developing countries regarding dystonia, which boosts the growth of the dystonia drugs market trends. People are also becoming aware about the condition and its treatment options, which increases the prescribing of dystonia drugs by the practitioner. For instance, September of every year is celebrated as dystonia awareness month. In this month, The Dystonia Society of UK, works on raising awareness among the population and understanding the condition better. Such initiatives taken up by the government and non-

government organizations increase awareness among the people regarding the condition, and the need for its treatment. Thus, boost the growth of the market.

In addition, increase in demand for novel therapies for the treatment of neurological conditions along with increase in demand for these therapies in emerging countries and countries with high population base such as China and India are boosting the growth of the dystonia drugs market. Moreover, an increase in investments by the key players from developed countries into emerging economies is anticipated to offer lucrative opportunity for the growth of the market.

On the basis of drug type, the dystonia drugs industry is segmented into dopaminergic agents, GABAergic agents, anticonvulsants drugs, and others. The GABAergic agents segment exhibited highest growth in 2021 and is expected to remain dominant during the forecast period, owing increase in demand and prescribing of GABAergic agents in dystonia treatment and rise incidences of dystonia around the globe.

On the basis of route of administration, the market is segmented into oral and injections segment. The oral route of administration dominated the market in 2021, owing to rise in preference by high population, and cost-effective medications. On the other hand, injectable segment is expected to grow at a fastest CAGR during the forecast period, owing to increasing R&D activities in the Botulinum toxin injections and adoption of Botox in dystonia treatment.

On the basis of distribution channel, the market is segmented into hospital pharmacies, online providers and drug stores and retail pharmacies. The drug stores and retail pharmacies exhibited the highest growth in 2021, owing to the increase in number of drug stores and pharmacies around the globe, and due to easy availability of dystonia medications in the drug store. On the other hand, the online providers segment is anticipated to grow at the fastest rate owing to easy accessibility of medications and doors step delivery services. In addition, the pandemic has created many shifts in consumer behavior, and one of the most impactful changes is the buying drugs from e-commerce websites, which is also anticipated to boost the segment growth.

Region wise, North America obtained the highest dystonia drugs market share in 2021, owing to the rise in incidences of dystonia in this region along with increase in prevalence of other neurological conditions causing dystonia. On the other hand, Asia-Pacific is expected to witness highest growth during the forecast period, owing to factors such as rise in investments in manufacturing of high-quality products by major key players, and availability of raw materials for manufacturing of dystonia medications.

Key Findings Of The Study

· By drug type, the GABAergic agents' segment was highest contributor to the market in 2021 and is estimated to be the fastest growing segment during the forecast period.

· By route of administration, the oral route of administration dominated the market in 2021 in terms of revenue.

· On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in 2021. However, online providers segment is anticipated to grow at the highest CAGR during the forecast period

· Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period